Filing Details
- Accession Number:
- 0001127602-12-025539
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-08-31 18:00:10
- Reporting Period:
- 2012-08-30
- Filing Date:
- 2012-08-31
- Accepted Time:
- 2012-08-31 18:00:10
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
318154 | Amgen Inc | AMGN | Biological Products, (No Disgnostic Substances) (2836) | 953540776 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1016369 | D Leonard Schaeffer | One Amgen Center Drive Thousand Oaks CA 91320-1799 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-08-30 | 5,000 | $74.89 | 21,316 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-08-30 | 5,000 | $83.25 | 16,316 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Nqso (Right to Buy) | Disposition | 2012-08-30 | 5,000 | $0.00 | 5,000 | $74.89 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2006-03-15 | 2013-03-15 | No | 4 | M | Direct |
Footnotes
- The price reported is an average price. The prices ranged from $83.23 to $83.26 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.
- These shares include 61 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's unvested, and vested but deferred, Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.